Abstract L-DOPA remains a cornerstone treatment for Parkinsons disease and is increasingly recognized for its role in various neurological and neurodegenerative disorders
The antioxidative enzymes (Cat, GR, and GPx) are negatively associated with the severity of the symptoms evaluated by the FIQR as overall functioning, pain, psychological distress, and sleep
Our team will review your health history and current medications during your consultation to confirm whether a GLP-1 program is right for you
Decreased appetite, which is technically the desired effect but can feel uncomfortable when it is extreme
The rules have limited who can get these medications because of their cost.
Real-world data shows adherence to weekly GLP-1 therapy can fall to 17% after two years , and the 18 to 24 month period is described as a critical window where accessible support may help prevent drop-off and regain, according to the AMCP GLP-1 FAQ